Since 1990, testosterone has been classified as a Schedule III controlled substance in the United States — the same category as ketamine, certain barbiturates, and anabolic steroids. This classification affects every aspect of how testosterone therapy is prescribed, dispensed, monitored, and perceived.

In December 2025, an FDA expert panel recommended removing this classification entirely. If that recommendation is adopted, it would represent the most significant change in testosterone regulation in over three decades.

Here's what the current scheduling means, why it exists, and what descheduling could change for TRT patients.

What Does "Schedule III" Actually Mean?

The Controlled Substances Act divides drugs into five schedules based on their potential for abuse, accepted medical use, and safety profile. Schedule III drugs are defined as having "a moderate to low potential for physical and psychological dependence."

In practical terms, Schedule III classification means:

Why Testosterone Was Scheduled in the First Place

The story of how testosterone became a controlled substance is more about politics than pharmacology.

In the late 1980s, a series of high-profile doping scandals — particularly in Olympic sports and professional athletics — created public pressure to crack down on anabolic steroids. Congress responded with the Anabolic Steroids Control Act of 1990, which placed testosterone and its derivatives under Schedule III.

As Dr. Landon Trost explained at the December 2025 FDA panel, the decision wasn't evidence-based. There is no clinical evidence that testosterone at therapeutic doses causes physical dependency in the way that opioids or benzodiazepines do. The scheduling was aimed at preventing abuse by athletes and bodybuilders — not at regulating legitimate medical treatment for hypogonadism.

Dr. Trost also pointed out that the intended effect didn't even work: while illicit steroid use initially declined after the 1990 Act, it rebounded and actually exceeded pre-1990 levels within 10 years. Meanwhile, the controlled substance designation created lasting barriers for the men who needed testosterone for legitimate medical reasons.

How Scheduling Creates Barriers to Care

The practical impact of Schedule III classification goes far beyond paperwork:

Primary care avoidance. Many general practitioners are uncomfortable prescribing controlled substances — especially hormones they weren't trained on extensively in medical school. The controlled substance label adds a layer of regulatory scrutiny that makes some doctors avoid testosterone entirely, even when it's clinically appropriate.

The "T clinic" phenomenon. Because mainstream medicine has been slow to embrace TRT, a parallel industry of specialized testosterone clinics has emerged. As Dr. Trost noted: "Because of that, you get these pop-up T clinics and other things that will fill that gap, whereas normally the patient would be going to their primary care physician."

Telehealth uncertainty. The DEA's temporary telemedicine flexibilities for controlled substances — which allow doctors to prescribe testosterone via video consultation without a prior in-person visit — are currently extended only through December 31, 2026. If these expire without permanent rules, millions of men could lose access to their TRT providers overnight.

Insurance friction. The controlled substance designation doesn't directly prevent insurance coverage, but it creates additional prior authorization requirements and prescribing hurdles that can delay or deny coverage.

The Estrogen Double Standard

Perhaps the most compelling argument for descheduling testosterone is the comparison to estrogen.

Estrogen — the primary female sex hormone — is prescribed for hormone replacement therapy in women. It is not a controlled substance. It never has been. There are no DEA registration requirements, no PDMP tracking, no special pharmacy security measures.

Both testosterone and estrogen are hormones prescribed to replace what the body no longer produces adequately. Both carry real risks that require medical monitoring. Both can be misused. Yet only one is regulated as though it were a narcotic.

Dr. Khera made this point directly at the FDA panel: "We give patients clomiphene, which raises testosterone. We give patients HCG, which raises testosterone. None of these are controlled substances, but they do the exact same thing. They're raising testosterone."

The Core Issue

Testosterone is the only hormone in the U.S. that is classified as a controlled substance. Estrogen, progesterone, thyroid hormones, insulin, and medications that raise testosterone (like clomiphene and HCG) are all unscheduled. The panel argues there is no scientific basis for this inconsistency.

What Descheduling Would Change

If testosterone is removed from the controlled substances list, here's what would change for patients:

Easier prescribing. Your family doctor or internist could prescribe testosterone without a DEA registration, making primary care a more viable path to treatment. Fewer administrative hoops means more doctors willing to offer TRT.

Telehealth stability. The biggest practical impact would be on online TRT clinics. Without controlled substance restrictions, the telehealth prescribing question becomes much simpler — no more relying on temporary DEA extensions that could expire.

Potential cost reductions. Controlled substance supply chains carry additional costs for security, tracking, and compliance. Removing these requirements could reduce costs at the pharmacy and distributor levels, potentially lowering prices for patients.

Reduced stigma. The "controlled substance" label carries cultural weight. Many men associate testosterone with illegal steroids or performance-enhancing drugs. Descheduling would help reframe TRT as what it is: a standard hormone replacement therapy, no different in principle from thyroid medication or insulin.

What wouldn't change: Testosterone would still be a prescription medication. You'd still need a doctor's evaluation, bloodwork, and ongoing monitoring. Descheduling doesn't mean deregulation — it means regulating testosterone the same way we regulate other hormones.

When Could This Actually Happen?

Here's where it gets complicated. Descheduling is not solely an FDA decision — it requires action from the DEA, which operates under the Department of Justice. The process involves:

  1. FDA recommending a scheduling change to the DEA (or the DEA initiating its own review)
  2. DEA conducting its own analysis of abuse potential, medical use, and safety
  3. A formal rulemaking process with public comment periods
  4. Final rule publication

This process typically takes 2-5 years, and there's no guarantee of a specific outcome. Political dynamics could accelerate or slow the process. The current regulatory environment under FDA Commissioner Makary appears receptive, but administrations change.

Near-term (2026): The FDA public comment period continues. Expect more visibility and media coverage as the descheduling discussion enters mainstream awareness.

Medium-term (2027-2028): If the FDA formally recommends descheduling to the DEA, the regulatory process would begin in earnest.

Possible alternative: Instead of full descheduling, testosterone could be rescheduled to Schedule V (the lowest level of control, like certain cough syrups) or moved to a non-scheduled prescription-only status. Either would significantly reduce the current barriers.

Regardless of the exact timeline, the direction of travel is clear. The medical community, the FDA advisory panel, and an increasing number of regulatory voices agree that testosterone's current classification doesn't reflect the science. Change is coming — the question is when, not if.

Don't Wait for Regulations to Catch Up

TRT is available now through both in-person and online providers. Our clinic comparison helps you find the right fit for your needs and budget.

See Our 2026 Clinic Rankings →